HIVDrugSettlement.com
(877) 999-2491

This official website is maintained by the Settlement Administrator retained and supervised by Settlement Class Counsel in the case entitled Staley, et al., v. Gilead Sciences, Inc., et al.

Antiretroviral Medication Class Action

What is this Lawsuit About?

THE DEADLINE TO FILE A CLAIM HAS PASSED.

A partial settlement has been reached in a class action lawsuit involving the antiretroviral drugs Atripla, Biktarvy, Complera, Descovy, Evotazz, Odefsey, Prezcobix, Stribild, Symtuza, Truvada, and Viread (the "Settlement").

The lawsuit claims that Gilead Sciences, Inc., Gilead Holdings, LLC, Gilead Sciences, LLC, and Gilead Sciences Ireland UC ("Gilead"), Bristol-Myers Squibb Company and E. R. Squibb & Sons, L.L.C. ("BMS"), and Johnson & Johnson, Janssen Products LP, and Janssen R&D Ireland ("Janssen") (collectively, "Defendants") engaged in a variety of allegedly anticompetitive conduct that caused certain consumers and third-party payors (the "End-Payor Class") to pay too much for HIV medicines, specifically: Atripla, Biktarvy, Complera, Descovy, Evotaz, Genvoya, Odefsey, Prezcobix, Stribild, Symtuza, Truvada, and Viread. Defendants deny any wrongdoing. For additional details and answers to frequently asked questions, please read the Long-Form Notice.

If you are a consumer member of the Atripla Settlement Damages Class or the Evotaz Settlement Damages Class you may file a claim now. If you are a TPP member of a Settlement Damages Class, you will be notified when to submit a Claim Form. Payments to eligible consumers of Atripla and Evotaz will vary based on the number of claims, but are expected to average $70.50 to $282.

Generally, you are included in the Atripla Settlement Damages Class if you reside in the United States or its territories and you purchased, paid, and/or provided reimbursement in (which shall include, with respect to TPPs, the state in which you have your principal place of business) any of the Damages States for some or all of the purchase price for brand or generic Atripla, sold by Bristol-Myers Squibb Company or its affiliates, by Gilead Sciences, Inc. or its affiliates, or by Teva Pharmaceutical Industries Ltd. or its affiliates, for consumption by yourself or your family, or, with respect to TPPs, by your members, employees, insureds, participants, citizens, residents, or beneficiaries, other than for resale, during the period May 14, 2015, through and until October 13, 2021. The Atripla Settlement Damages Class includes Third-Party Payors (“TPPs”) and individual consumers.

Generally, you are included in the Evotaz Settlement Damages Class if you reside in the United States or its territories and you purchased, paid, and/or provided reimbursement in (which shall include, with respect to TPPs, the state in which you have your principal place of business) any of the Damages States for some or all of the purchase price of Evotaz, for consumption by yourself or your family, or, with respect to TPPs, by your members, employees, insureds, participants, citizens, residents, or beneficiaries, other than for resale, during the period May 14, 2015, through and until October 13, 2021. The Evotaz Settlement Damages Class includes TPPs and individual consumers.

IMPORTANT DATES

Exclusion Deadline
April 6, 2022

Objection Deadline
April 6, 2022

Claim Filing Deadline
60 days after the final approval of the Settlement

Final Approval Hearing
April 28, 2022

CONSUMER CLASS MEMBERS CAN OBJECT TO THE SETTLEMENT, OPT OUT OF THE SETTLEMENT, OR MAKE A CLAIM WITHOUT THEIR IDENTITIES BEING MADE PUBLIC.

Your Legal Rights and Options

If you are a member of one of more of the Settlement Damages Classes:
FILE A CLAIM
If you are a consumer member of the Atripla Settlement Damages Class or the Evotaz Settlement Damages Class you may file a claim by obtaining a Claim Form from the website www.HIVdrugsettlement.com or requesting one from the Settlement Administrator and submitting it via the website or the mailing address listed on the Contact Page of this website. Your identity will not be made public during any part of the claims process. If you choose not to file a claim, and do not exclude yourself, you will still be bound by the settlement but will not receive any damages award. If you are a TPP member of a Settlement Damages Class, you will be notified when to submit a Claim Form.
EXCLUDE YOURSELF FROM THE SETTLEMENT CLASSES
You may write to the Settlement Administrator, A.B. Data, and exclude yourself from the Settlement Damages Classes, which allows you to file a lawsuit against BMS that asserts damages claims related to the allegations or claims in this case. The exclusion deadline is April 6, 2022. Your identity will not be made public during any part of the exclusion process.
OBJECT TO THE SETTLEMENT
You may write to the Court and explain what you do not like about the Settlement. The objection deadline is April 6, 2022. Additionally, you may ask to go to the Final Approval Hearing and speak in Court about the fairness of the Settlement. Your notice of intention to appear at the Final Approval Hearing must be postmarked no later than April 6, 2022. If you object to the settlement, you are still a part of the damages class and you must file a claim in order to receive a damages award. Without your express consent, your identity will not be made public during any part of the objection process.
If you are a member of one of more of the Settlement Injunctive-Relief Classes:
DO NOTHING
You will be able to participate as a Settlement Class Member in the settlement and you will give up rights to be part of any other lawsuit that asserts certain claims related to the allegations or claims against BMS in this case.
OBJECT TO THE SETTLEMENT
You may write to the Court and explain what you do not like about the Settlement. The objection deadline is April 6, 2022. Additionally, you may ask to go to the Final Approval Hearing and speak in Court about the fairness of the Settlement. Your notice of intention to appear at the Final Approval Hearing must be postmarked no later than April 6, 2022. Without your express consent, your identity will not be made public during any part of the objection process.